...
首页> 外文期刊>Behavioural Brain Research: An International Journal >PPAR beta/delta agonist alleviates NLRP3 inflammasome-mediated neuroinflammation in the MPTP mouse model of Parkinson's disease
【24h】

PPAR beta/delta agonist alleviates NLRP3 inflammasome-mediated neuroinflammation in the MPTP mouse model of Parkinson's disease

机译:PPARβ/δ激动剂缓解NLRP3炎症内介导的帕金森病的MPTP小鼠模型中的神经炎炎症

获取原文
获取原文并翻译 | 示例

摘要

Recent studies have indicated that peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) agonists exert neuroprotective effects in the model of Parkinson's disease (PD). Furthermore, PPARI beta/delta agonists have been shown to have potential anti-inflammatory activity, but the underlying mechanisms remain obscure. Emerging evidence indicates that the nucleotide-binding domain and leucine-rich-repeat-protein 3 (NLRP3) inflammasome-mediated neuroinflammation plays a crucial role in the pathogenesis of PD. In the present study we investigate whether PPAR beta/delta agonists alleviate NLRP3-mediated neuroinflammation in the 1- methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) mouse model of PD. We administered GW501516, a selective and highaffinity PPAR beta/delta agonist, via intracerebroventricular infusion. Locomotor activities were tested by open field tests and the pole test. The levels of dopamine and its metabolites were determined using highperformance liquid chromatography.Dopaminergic neurodegeneration was assessed via Western blot analysis. The levels of oxidative stress were detected via spectrophotometric assays. The expressions of pro-inflammatory cytokines were measured by performing quantitative real-time RT-PCR and ELISA. Western blot analysis was used to assess NLRP3 inflammasome activation. Our results show that GW501516 reduced movement impairment in PD mice; furthermore, it attenuated dopaminergic neurodegeneration in the midbrain and the depletion of dopamine in the striatum and it inhibited inflammatory reactions and NLRP3 inflammasome activation in the midbrain of PD mice. More importantly, it attenuated astrocytic reaction but had no significant effect on microglial reaction in the midbrain of PD mice. Collectively, our findings demonstrate for the first time that the specific PPARI beta/delta agonist GW501516 alleviates NLRP3 inflammasome-mediated neuroinflammation in astrocytes in the MPTP mouse model of PD.
机译:最近的研究表明过氧化物体增殖物激活的受体β/ delta(PPARβ/ delta)激动剂在帕金森病(Pd)的模型中发挥神经保护作用。此外,PPARIβ/δ激动剂已被证明具有潜在的抗炎活动,但潜在的机制仍然模糊不清。出现的证据表明,核苷酸结合结构域和富含亮氨酸富含重复蛋白3(NLRP3)炎症组介导的神经炎性炎症在PD的发病机制中起着至关重要的作用。在本研究中,我们研究了PPARβ/δ激动剂是否在1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)小鼠的Pd中的NLRP3介导的神经炎症中的NLRP3介导的神经炎症。我们通过IntraceBrentriculary输注给药GW501516,一种选择性和高分位PPARβ/δ激动剂。开车运动由开放式测试和杆测试进行测试。使用高矿液相色谱法测定多巴胺和其代谢物的水平。通过蛋白质印迹分析评估红胺能神经变性。通过分光光度法检测氧化应激水平。通过进行定量实时RT-PCR和ELISA测量促炎细胞因子的表达。 Western印迹分析用于评估NLRP3炎症组活化。我们的研究结果表明,GW501516降低了PD老鼠的运动损伤;此外,它在中脑中减弱多巴胺能神经变性和纹状体中的多巴胺的耗尽,并且它抑制了Pd小鼠中脑中的炎症反应和NLRP3炎症组活化。更重要的是,它衰减星形胶质反应,但对Pd小鼠中脑中的微胶质反应没有显着影响。集体,我们的研究结果首次证明了特定的PPARIβ/δ激动剂GW501516在PD的MPTP小鼠模型中的星形胶质细胞中减轻了NLRP3炎症组介导的神经炎炎症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号